Early breast cancer and risk stratification eLearning

Dr Laura Spring, MD, is a Medical Oncologist and clinical researcher at the Massachusetts General Hospital Cancer Center and Harvard Medical School. Dr Spring is particularly interested in targeted therapies in the neoadjuvant setting and has conducted multiple breast cancer research trials for localised metastatic breast cancer.

Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany. Professor Harbeck is a member of the expert panel issuing the yearly updated evidence based AGO Guidelines for breast cancer therapy in Germany. She is a panel member of several international breast cancer consensus conferences and is the recipient of many awards, including the 2020 ESMO Lifetime Achievement Award.

Stephen Johnston is Professor of Breast Cancer Medicine, Consultant Medical Oncologist and Head of The Breast Unit at the Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London. He was appointed Head of Medical Oncology at The Royal Marsden in 2019, having previously been the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre for Cancer at The Royal Marsden from 2006-12.He is actively involved in facilitating the interface between basic and applied research and has been Chief Investigator of several phase II / III trials of novel endocrine-based therapeutic approaches in both advanced and early-stage disease, including one of the large global adjuvant CDK4/6 inhibitor studies in early breast cancer.